The most common complaint among people using GLP-1 receptor agonists for weight loss has nothing to do with nausea, injection anxiety, or food costs. It's fatigue. Persistent, crushing, "why did I even start this" exhaustion that makes you question whether losing 15% of your body weight is worth feeling like you're running on half a battery.

Retatrutide — the triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously — is the most powerful weight loss compound to emerge from clinical trials. Phase 2 data showed participants losing up to 24.2% body weight at 48 weeks. But with that metabolic firepower comes a predictable consequence: your body burns through energy substrates faster than it can replace them, and cellular energy production takes a direct hit.

This is where NAD+ enters the equation. Not as a trendy supplement, but as a targeted intervention to address the specific metabolic bottleneck that GLP-1 peptides create.

Why GLP-1 peptides cause fatigue: the cellular energy problem

To understand why retatrutide causes fatigue, you need to understand what happens inside your mitochondria during aggressive caloric deficit.

GLP-1 agonists reduce food intake by 25-40%. Your body responds by shifting from glucose-dominant metabolism to increased fatty acid oxidation. This is good for fat loss. But the switch isn't free. Fatty acid beta-oxidation requires NAD+ as a cofactor at every step. The citric acid cycle requires NAD+. The electron transport chain requires NAD+. Every metabolic pathway your body relies on during a caloric deficit is NAD+-dependent.

Here's the problem: NAD+ levels decline naturally with age — roughly 50% by age 50 compared to age 20. Layer a severe caloric deficit on top of already-depleted NAD+ pools, and your mitochondria simply cannot produce ATP at the rate your body demands. The result is fatigue that sleep doesn't fix, brain fog that coffee doesn't clear, and exercise intolerance that makes you wonder if you're getting weaker instead of healthier.

Retatrutide amplifies this effect beyond what semaglutide or tirzepatide produce, because the glucagon receptor activation increases basal metabolic rate by 15-20%. Your cells are burning more energy while having less substrate to work with. Without adequate NAD+, this equation breaks down badly.

NAD+ supplementation: direct substrate replacement

Injectable NAD+ bypasses the conversion bottleneck that oral precursors (NMN, NR) face. When you inject NAD+ subcutaneously, you're delivering the finished cofactor directly into tissue. No waiting for enzymatic conversion. No hoping your gut absorbs enough precursor. No competition with other metabolic demands for the same enzymes.

The relevant pharmacology for peptide users:

• Mitochondrial support: NAD+ is required for complexes I, II, and III of the electron transport chain. Replenishing depleted stores directly increases ATP production capacity.
• Sirtuin activation: SIRT1 and SIRT3 are NAD+-dependent enzymes that regulate mitochondrial biogenesis, fatty acid oxidation efficiency, and cellular stress response. These pathways are critical during caloric restriction.
• DNA repair maintenance: PARP enzymes consume NAD+ during DNA repair. Caloric deficit and increased metabolic activity generate more oxidative stress, demanding more repair. Without surplus NAD+, repair competes with energy production.
• Neurotransmitter synthesis: Brain fog during weight loss partly stems from impaired tryptophan-to-serotonin conversion and dopamine synthesis, both of which require adequate NAD+ levels.

This isn't speculative biochemistry. These are established metabolic pathways. The question isn't whether NAD+ matters during aggressive weight loss — it's whether exogenous supplementation makes a measurable difference in how you feel and perform.

The stack: practical dosing protocol

Based on available clinical data and established dosing conventions for both compounds, here is a practical protocol for combining retatrutide with NAD+.

Retatrutide dosing (standard titration)

Weeks	Dose	Frequency
1–4	1 mg	Once weekly
5–8	2 mg	Once weekly
9–12	4 mg	Once weekly
13–16	8 mg	Once weekly
17+	12 mg	Once weekly

For those preferring the convenience of a pre-loaded device, the Retatrutide Pen eliminates the need for manual reconstitution and drawing doses.

NAD+ dosing

Phase	Dose	Frequency	Purpose
Loading (weeks 1–2)	100–200 mg	3x per week, subcutaneous	Rapidly restore depleted NAD+ pools
Maintenance	100 mg	2x per week, subcutaneous	Sustain mitochondrial function
High-deficit days	50–100 mg	As needed	Counter acute fatigue episodes

The NAD+ Pen is practical here — particularly for maintenance dosing where consistent, accurate delivery matters more than flexibility.

Timing considerations

• Retatrutide injection: Same day each week, morning preferred. Many users report better GI tolerance with morning dosing on a light stomach.
• NAD+ injection: Separate from retatrutide by at least 24 hours. Inject in the morning on non-retatrutide days for peak energy support during waking hours.
• Don't combine injection sites: Use abdomen for one compound, thigh for the other. Rotate within each zone.

What to expect: timeline of effects

Weeks 1–4 (titration phase)

Retatrutide at 1–2 mg produces mild appetite suppression with minimal side effects for most users. Adding NAD+ during this phase serves as preloading — building cellular reserves before the metabolic demand increases. Most users report improved mental clarity and slightly better sleep quality within the first 7–10 days of NAD+ loading.

Weeks 5–12 (active weight loss begins)

This is where the stack proves its value. At 4–8 mg retatrutide, appetite suppression becomes significant and caloric deficit deepens. Users without NAD+ support typically report their worst fatigue during weeks 6–10. With NAD+ maintenance dosing, most report energy levels staying at 70–85% of baseline rather than the 40–60% that GLP-1 peptides alone tend to produce.

Expected fat loss during this window: 1–2 kg per week, depending on starting weight and dietary adherence.

Weeks 13+ (maintenance dose territory)

At 8–12 mg retatrutide, weight loss accelerates to peak rates. The glucagon receptor activation is fully engaged, driving increased energy expenditure. NAD+ maintenance dosing at this stage isn't optional — it's the difference between functional weight loss and the kind of exhaustion that makes people quit.

Users running this full stack through 24+ weeks consistently report better workout capacity, stable mood, fewer brain-fog episodes, and the ability to maintain social and professional obligations without the "zombie mode" that high-dose GLP-1 monotherapy often creates.

Managing side effects from both compounds

Retatrutide-specific

• Nausea: Most common at dose increases. Eat small, frequent meals. Ginger tea helps. If severe, stay at current dose for an extra week before escalating.
• Diarrhea: The glucagon component causes this more than pure GLP-1 agonists. Usually resolves within 2–3 weeks at each dose level.
• Decreased appetite: This is the mechanism, not a side effect. But ensure minimum 1,200 kcal (women) / 1,500 kcal (men) daily to prevent excessive muscle loss.

NAD+-specific

• Injection site flushing: Common with subcutaneous NAD+. Mild warmth and redness lasting 15–30 minutes. Ice the site pre-injection to reduce this.
• Nausea (rare): Can occur at higher doses. If it overlaps with retatrutide GI effects, reduce NAD+ dose to 50 mg and titrate back up.
• Chest tightness: Very rare at subcutaneous doses. More common with IV protocols. If experienced, reduce dose and inject more slowly.

Who this stack is designed for

This combination makes the most sense for:

• Users who tried semaglutide or tirzepatide and quit due to fatigue
• People over 35 whose baseline NAD+ levels are already declining
• Anyone running retatrutide at 8 mg+ who needs to maintain work or training performance
• Athletes or active individuals who can't afford the energy crash that GLP-1 peptides typically impose

It makes less sense for someone on low-dose retatrutide (1–2 mg) with minimal side effects, or for someone who responds well to oral NMN/NR supplementation alone.

Lab markers worth tracking

If you're running this stack for more than 8 weeks, the following bloodwork at baseline and every 12 weeks gives you objective feedback:

• Fasting glucose and HbA1c: Retatrutide dramatically improves glycemic control. Track the improvement.
• Live...